Q91.5
Trisomy 13, mosaicism (mitotic nondisjunction)
Clinical Classification Guidelines
Medical Intelligence & Overview
Trisomy 13 mosaicism, also known as mosaic trisomy 13, is a genetic condition caused by the presence of extra copies of chromosome 13 in some cells of the body. Unlike full trisomy 13, where all cells carry the abnormality, mosaicism means only a portion of the body's cells are affected. This condition results from a process called mitotic nondisjunction, where chromosomes do not separate properly during cell division after conception. The number of affected cells can vary widely, influencing the severity of symptoms and health outcomes.
Causes & Symptoms
Clinical Causes: Mitotic nondisjunction during early embryonic cell division leads to mosaicism. Genetic mutation occurs after fertilization, resulting in some cells with an extra chromosome 13. In most cases, the exact cause of nondisjunction is unknown, but it may be influenced by factors such as advanced maternal age or environmental exposures. There is no indication of inherited transmission; this is an sporadic genetic event.
Key Symptoms: Variable physical abnormalities depending on the proportion of affected cells. Facial features such as cleft lip or palate, low-set ears, and a small jaw. Clenched fists with overlapping fingers. Decreased muscle tone (hypotonia) and developmental delays. Congenital heart defects, common in mosaic trisomy 13 cases. Malformations of the brain, kidneys, or other vital organs. Possible eye abnormalities or vision problems. Seizures or neurological issues in some cases. Growth retardation and failure to thrive.
Diagnostic & Treatment
Diagnosis Path: Diagnosis is typically made through chromosomal analysis, such as karyotyping, fluorescence in situ hybridization (FISH), or chromosomal microarray, performed on samples from blood, skin, or other tissues. These tests detect the presence of extra chromosome 13 in some cells, confirming mosaicism. Prenatal testing options include amniocentesis or chorionic villus sampling to identify the condition before birth. Postnatal diagnosis involves physical examination and genetic testing to determine the proportion of affected cells.
Treatment Protocols: Management of Trisomy 13 mosaicism focuses on addressing specific symptoms and health issues. This may include surgical interventions for structural anomalies, therapies to support development, and ongoing medical care for associated conditions such as heart defects. Since the severity varies, treatment plans are individualized. Early intervention and multidisciplinary approaches are critical for optimizing quality of life. Regular monitoring by healthcare professionals helps manage evolving health needs.
Clinical Advice & FAQs
Billing Guidance
Is Q91.5 a billable ICD-10 code?
Yes, Q91.5 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Q91.5?
Clinical documentation must specify the nature of Trisomy 13, mosaicism (mitotic nondisjunction) and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
